These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32421352)

  • 41. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.
    Cholon DM; Quinney NL; Fulcher ML; Esther CR; Das J; Dokholyan NV; Randell SH; Boucher RC; Gentzsch M
    Sci Transl Med; 2014 Jul; 6(246):246ra96. PubMed ID: 25101886
    [TBL] [Abstract][Full Text] [Related]  

  • 42. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis.
    Gramegna A; Contarini M; Aliberti S; Casciaro R; Blasi F; Castellani C
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.
    Munce D; Lim M; Akong K
    Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 46. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
    Deeks ED
    Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of personalised therapies on respiratory medicine.
    Elborn JS
    Eur Respir Rev; 2013 Mar; 22(127):72-4. PubMed ID: 23457168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ivacaftor for the treatment of cystic fibrosis in children under six years of age.
    Aoyama BC; Mogayzel PJ
    Expert Rev Respir Med; 2020 Jun; 14(6):547-557. PubMed ID: 32154747
    [No Abstract]   [Full Text] [Related]  

  • 49. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis.
    Grasemann H; Gonska T; Avolio J; Klingel M; Tullis E; Ratjen F
    J Cyst Fibros; 2015 Nov; 14(6):727-32. PubMed ID: 26168933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
    Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
    J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.
    Birket SE; Davis JM; Fernandez-Petty CM; Henderson AG; Oden AM; Tang L; Wen H; Hong J; Fu L; Chambers A; Fields A; Zhao G; Tearney GJ; Sorscher EJ; Rowe SM
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1271-1282. PubMed ID: 32584141
    [No Abstract]   [Full Text] [Related]  

  • 53. Ivacaftor in a young boy with the rare gating mutation S549R--use of lung clearance index to track progress: a case report.
    Lenherr N; Lurà M; Trachsel D; Latzin P; Hammer J
    BMC Pulm Med; 2015 Oct; 15():123. PubMed ID: 26474553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
    Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
    Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
    [No Abstract]   [Full Text] [Related]  

  • 55. Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T - a case report.
    Welsner M; Straßburg S; Taube C; Sutharsan S
    BMC Pulm Med; 2019 Apr; 19(1):76. PubMed ID: 30975115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
    Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
    Chest; 2013 Jan; 143(1):14-18. PubMed ID: 23276841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.
    Milla CE; Ratjen F; Marigowda G; Liu F; Waltz D; Rosenfeld M;
    Am J Respir Crit Care Med; 2017 Apr; 195(7):912-920. PubMed ID: 27805836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
    Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
    Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.